You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBupivacaine
Accession NumberDB00297  (APRD00247)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA widely used local anesthetic agent. [PubChem]
Structure
Thumb
Synonyms
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Bupivacaina
Bupivacainum
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
racemic bupivacaine
External Identifiers
  • DUR-843
  • LAC-43
  • SKY-0402
  • SKY0402
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; intracaudalHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltration; intracaudalHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; retrobulbarHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltration; intracaudalHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; retrobulbarHospira, Inc.1978-04-17Not applicableUs
Bupivacaine Hydrochloride Injection USPsolution5 mgblock/infiltrationMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPsolution2.5 mgblock/infiltration; epiduralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPsolution2.5 mgblock/infiltrationMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPsolution5 mgblock/infiltration; epiduralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPsolution7.5 mgretrobulbar; epiduralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USP .25%solution2.5 mgblock/infiltration; intracaudal; epiduralHospira Healthcare Corporation1996-07-302011-08-05Canada
Bupivacaine Hydrochloride Injection USP .50%solution5 mgblock/infiltration; intracaudal; epiduralHospira Healthcare Corporation1996-07-302011-08-05Canada
Bupivacaine Hydrochloride Injection USP .75%solution7.5 mgblock/infiltration; intracaudal; epiduralHospira Healthcare Corporation1996-07-302011-08-05Canada
Bupivacaine Injection BPsolution5 mgblock/infiltration; epiduralSterimax Inc2016-05-20Not applicableCanada
Bupivacaine Injection BPsolution2.5 mgblock/infiltration; epiduralSterimax Inc2016-05-20Not applicableCanada
Exparelinjection, suspension, liposomal13.3 mg/mLinfiltrationPacira Pharmaceuticals Inc.2016-01-01Not applicableUs
Exparelinjection, suspension, liposomal13.3 mg/mLinfiltrationPacira Pharmaceuticals Inc.2012-01-01Not applicableUs
Jamp-bupivacainesolution5 mgblock/infiltration; epiduralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-bupivacainesolution5 mgblock/infiltrationJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-bupivacainesolution2.5 mgblock/infiltration; epiduralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-bupivacainesolution2.5 mgblock/infiltrationJamp Pharma CorporationNot applicableNot applicableCanada
Marcaineinjection, solution2.5 mg/mLepidural; infiltrationHospira, Inc.1972-10-03Not applicableUs
Marcaineinjection, solution5 mg/mLepiduralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Marcaineinjection, solution5 mg/mLinfiltrationHospira, Inc.1972-10-03Not applicableUs
Marcaineinjection, solution5 mg/mLepiduralREMEDYREPACK INC.2015-03-07Not applicableUs
Marcaineinjection, solution5 mg/mLepidural; infiltrationHospira, Inc.1972-10-03Not applicableUs
Marcaineinjection, solution7.5 mg/mLepidural; retrobulbarA S Medication Solutions Llc2009-09-09Not applicableUs
Marcaineinjection, solution7.5 mg/mLepidural; retrobulbarHospira, Inc.1972-10-03Not applicableUs
Marcaineinjection, solution2.5 mg/mLinfiltrationPhysicians Total Care, Inc.2009-09-08Not applicableUs
Marcaineinjection, solution5 mg/mLepiduralREMEDYREPACK INC.2013-06-12Not applicableUs
Marcaineinjection, solution2.5 mg/mLepidural; infiltrationCardinal Health2009-09-08Not applicableUs
Marcaineinjection, solution2.5 mg/mLinfiltrationHospira, Inc.1972-10-03Not applicableUs
Marcaineinjection, solution2.5 mg/mLepidural; infiltrationGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Marcaine 0.25%solution2.5 mgblock/infiltrationHospira Healthcare Corporation2008-10-08Not applicableCanada
Marcaine 0.25% Liq Prt 2.5mg/mlliquid2.5 mgblock/infiltration; epiduralSanofi Canada, Inc.1973-12-312001-08-10Canada
Marcaine 0.50%solution5.0 mgblock/infiltrationHospira Healthcare Corporation2008-09-17Not applicableCanada
Marcaine 0.50% Liq Bin 5mg/mlliquid5 mgblock/infiltration; epiduralSanofi Canada, Inc.1973-12-312001-08-10Canada
Marcaine 0.75% Liq Prt 7.5mg/mlliquid7.5 mgretrobulbar; epiduralSanofi Canada, Inc.1974-12-312001-08-10Canada
Marcaine 0.75% Liq Spinal 7.5mg/mlliquid7.5 mgintraspinalSanofi Canada, Inc.1979-12-312001-08-10Canada
Marcaine 2.5 mg/mlsolution2.5 mgblock/infiltration; epiduralHospira Healthcare Corporation2000-12-01Not applicableCanada
Marcaine 5 mg/mlsolution5.0 mgblock/infiltration; epiduralHospira Healthcare Corporation2000-12-01Not applicableCanada
Marcaine 7.5 mg/mlsolution7.5 mgretrobulbar; epiduralHospira Healthcare Corporation2001-09-15Not applicableCanada
Marcaine Spinalinjection, solution7.5 mg/mLsubarachnoidHospira, Inc.1984-05-04Not applicableUs
Marcaine Spinal 7.5 mg/mlsolution7.5 mgintraspinalHospira Healthcare Corporation2000-12-01Not applicableCanada
Sensorcaineinjection, solution5 mg/mLperineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaineinjection, solution2.5 mg/mLinfiltration; perineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaine 0.25%liquid2.5 mgblock/infiltration; epiduralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Sensorcaine 0.5%liquid5 mgblock/infiltration; epiduralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Sensorcaine Mpfinjection, solution5 mg/mLepidural; intracaudal; perineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaine Mpfinjection, solution2.5 mg/mLepidural; infiltration; intracaudal; perineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bupivacaineinjection, solution7.5 mg/mLsubarachnoidHospira, Inc.1987-12-11Not applicableUs
Bupivacaine Hydrochlorideinjection2.5 mg/mLinfiltrationGeneral Injectables & Vaccines, Inc2010-07-01Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; intracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalHospira, Inc.1987-03-03Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltration; intracaudalCardinal Health2010-01-07Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLinfiltrationHospira, Inc.1987-03-03Not applicableUs
Bupivacaine Hydrochlorideinjection5 mg/mLinfiltrationGeneral Injectables & Vaccines, Inc2010-07-01Not applicableUs
Bupivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; retrobulbarAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLinfiltrationHospira, Inc.1987-02-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalCardinal Health2010-01-06Not applicableUs
Bupivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; retrobulbarHospira, Inc.1987-03-03Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalHospira, Inc.1987-02-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution7.5 mg/mLepidural; retrobulbarAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; intracaudalHospira, Inc.1987-03-03Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine Hydrochlorideinjection, solution2.5 mg/mLepidural; infiltration; intracaudalCardinal Health2010-01-06Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; intracaudalHospira, Inc.1987-02-17Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; infiltration; intracaudalCardinal Health2010-01-07Not applicableUs
Bupivacaine Hydrochlorideinjection, solution5 mg/mLepidural; intracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Sensorcaineinjection, solution5 mg/mLperineuralGeneral Injectables & Vaccines, Inc2011-10-18Not applicableUs
Sensorcaineinjection, solution2.5 mg/mLinfiltration; perineuralGeneral Injectables & Vaccines, Inc2011-10-17Not applicableUs
Sensorcaine Mpfinjection, solution7.5 mg/mLepidural; retrobulbarFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaine Mpfinjection, solution7.5 mg/mLsubarachnoidFresenius Kabi USA, LLC2010-05-25Not applicableUs
Sensorcaine Mpfinjection, solution5 mg/mLepidural; intracaudal; perineuralGeneral Injectables & Vaccines, Inc2011-10-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BupivanSun
CarbostesinAstraZeneca
MarcainAstraZeneca
MarcainaAstraZeneca
Sensorcaine-MPFAstra Zeneca
Brand mixtures
NameLabellerIngredients
Bupivacaine HCl 0.5% and Epinephrine 1:200,000 InjectionNovocol Pharmaceutical Of Canada Inc
Bupivacaine Hydrochloride and EpinephrineGeneral Injectables & Vaccines, Inc
Disposable Convenience Kit (single Shot Epidural)True Fit Rx Llc
Fentanyl Citrate, Bupivacaine HClCantrell Drug Company
Gapeam BudibacAlvix Laboratories, LLC
MarcaineCarestream Health Inc.
Marcaine 0.5% and Epinephrine 1:200,000 LiqKodak Canada Inc.
Marcaine E 0.25% Liq PrtSanofi Canada, Inc.
Marcaine E 2.5 mg/mlHospira Healthcare Corporation
Marcaine E 5.0 mg/mlHospira Healthcare Corporation
Marcaine E Liq Prt 0.50%Sanofi Canada, Inc.
Marcaine With EpinephrineHospira, Inc.
Physicians Ez Use M-predProficient Rx LP
Readysharp-ATerrain Pharmaceuticals
Readysharp-KTerrain Pharmaceuticals
Readysharp-p40Terrain Pharmaceuticals
Readysharp-p80Terrain Pharmaceuticals
SensorcaineFresenius Kabi USA, LLC
Sensorcaine 0.25% With EpinephrineAstrazeneca Canada Inc
Sensorcaine 0.5% With EpinephrineAstrazeneca Canada Inc
Sensorcaine ForteDentsply Canada Limited
Sensorcaine MpfCardinal Health
VivacaineSeptodont, Inc.
Vivacaine (bupivacaine HCl 0.5% & Epinephrine 1:200,000 Inj, USP)Septodont Inc
Salts
Name/CASStructureProperties
Bupivacaine hydrochloride
18010-40-7
Thumb
  • InChI Key: SIEYLFHKZGLBNX-UHFFFAOYSA-N
  • Monoisotopic Mass: 324.196841267
  • Average Mass: 324.889
DBSALT000202
Bupivacaine hydrochloride monohydrate
73360-54-0
Thumb
  • InChI Key: HUCIWBPMHXGLFM-UHFFFAOYSA-N
  • Monoisotopic Mass: 342.2074059
  • Average Mass: 342.91
DBSALT001512
Categories
UNIIY8335394RO
CAS number38396-39-3
WeightAverage: 288.4277
Monoisotopic: 288.220163528
Chemical FormulaC18H28N2O
InChI KeyInChIKey=LEBVLXFERQHONN-UHFFFAOYSA-N
InChI
InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
IUPAC Name
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
SMILES
CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-arylamide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
PharmacodynamicsBupivacaine is a widely used local anesthetic agent. Bupivacaine is often administered by spinal injection prior to total hip arthroplasty. It is also commonly injected into surgical wound sites to reduce pain for up to 20 hours after surgery. In comparison to other local anesthetics it has a long duration of action. It is also the most toxic to the heart when administered in large doses. This problem has led to the use of other long-acting local anaesthetics:ropivacaine and levobupivacaine. Levobupivacaine is a derivative, specifically an enantiomer, of bupivacaine. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias and to cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression or both.
Mechanism of actionLocal anesthetics such as bupivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Bupivacaine binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, which prevents depolarization. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone. The analgesic effects of Bupivicaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia.
Related Articles
AbsorptionThe rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
Volume of distributionNot Available
Protein binding95%
Metabolism

Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4.

SubstrateEnzymesProduct
Bupivacaine
Not Available
2,6-pipecoloxylidineDetails
Route of eliminationOnly 6% of bupivacaine is excreted unchanged in the urine.
Half life2.7 hours in adults and 8.1 hours in neonates
ClearanceNot Available
ToxicityThe mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. The intravenous and subcutaneous LD 50 in mice is 6 to 8 mg/kg and 38 to 54 mg/kg respectively. Recent clinical data from patients experiencing local anesthetic induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis with bupivacaine within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bupivacaine Action PathwayDrug actionSMP00393
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9814
Blood Brain Barrier+0.936
Caco-2 permeable+0.6669
P-glycoprotein substrateSubstrate0.8435
P-glycoprotein inhibitor IInhibitor0.8582
P-glycoprotein inhibitor IINon-inhibitor0.7836
Renal organic cation transporterNon-inhibitor0.6471
CYP450 2C9 substrateNon-substrate0.7957
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.7045
CYP450 1A2 substrateInhibitor0.6863
CYP450 2C9 inhibitorNon-inhibitor0.9099
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.6205
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6066
Ames testNon AMES toxic0.8462
CarcinogenicityNon-carcinogens0.8859
BiodegradationNot ready biodegradable0.9729
Rat acute toxicity2.2574 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8283
hERG inhibition (predictor II)Inhibitor0.7851
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • International medicated systems ltd
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Injectioninfiltration2.5 mg/mL
Injectioninfiltration5 mg/mL
Injection, solutionepidural; infiltration; intracaudal2.5 mg/mL
Injection, solutionepidural; infiltration; intracaudal5 mg/mL
Injection, solutionepidural; intracaudal5 mg/mL
Injection, solutionepidural; retrobulbar7.5 mg/mL
Injection, solutioninfiltration2.5 mg/mL
Injection, solutioninfiltration5 mg/mL
Injectionepidural; infiltration; intracaudal
Injection, solutiondental; infiltration
Injection, solutionepidural; infiltration; intracaudal
Injection, solutionepidural; intracaudal
Solutionblock/infiltration2.5 mg
Solutionblock/infiltration5 mg
Solutionblock/infiltration; epidural5 mg
Solutionblock/infiltration; intracaudal; epidural2.5 mg
Solutionblock/infiltration; intracaudal; epidural5 mg
Solutionblock/infiltration; intracaudal; epidural7.5 mg
Injection, suspension, liposomalinfiltration13.3 mg/mL
Injection, solutionepidural
Kittopical
Injection, solutionepidural5 mg/mL
Injection, solutionepidural; infiltration2.5 mg/mL
Injection, solutionepidural; infiltration5 mg/mL
Liquidblock/infiltration
Solutionblock/infiltration5.0 mg
Liquidretrobulbar; epidural7.5 mg
Liquidintraspinal7.5 mg
Solutionblock/infiltration; epidural2.5 mg
Solutionblock/infiltration; epidural5.0 mg
Solutionretrobulbar; epidural7.5 mg
Liquidblock/infiltration; epidural
Injection, solutionsubarachnoid7.5 mg/mL
Solutionintraspinal7.5 mg
Injection, solutionepidural; infiltration
Injection, solutioninfiltration
Kit
Kitepidural; infiltration; intramuscular; intrasynovial; soft tissue; topical
Kitepidural; infiltration
Kitepidural; infiltration; intra-articular; intramuscular; topical
Kitepidural; infiltration; intra-articular; intralesional; intramuscular; soft tissue
Injection, solutioninfiltration; perineural
Injection, solutioninfiltration; perineural2.5 mg/mL
Injection, solutionperineural
Injection, solutionperineural5 mg/mL
Liquidblock/infiltration; epidural2.5 mg
Solutionblock/infiltration; epidural
Liquidblock/infiltration; epidural5 mg
Injection, solutionepidural; infiltration; intracaudal; perineural
Injection, solutionepidural; infiltration; intracaudal; perineural2.5 mg/mL
Injection, solutionepidural; intracaudal; perineural
Injection, solutionepidural; intracaudal; perineural5 mg/mL
Injection, solutionepidural; retrobulbar
Injection, solutionsubcutaneous
Solutionblock/infiltration
Prices
Unit descriptionCostUnit
Bupivacaine hcl powder18.36USD g
Sensorcaine-dextr 0.75% amp2.36USD ml
Marcaine spinal ampul0.93USD ml
Bupivacaine 0.5% on-q pump0.63USD ml
Bupivacaine hcl 0.5% on-q pump0.63USD ml
Bupivacaine 0.25% on-q pump0.62USD ml
Marcaine 0.25% vial0.26USD ml
Bupivacaine hcl-ns 0.0625%0.25USD ml
Bupivacaine-ns 0.1% on-q pump0.25USD ml
Sensorcaine 0.25% vial0.2USD ml
Bupivacaine hcl-ns 0.1%0.17USD ml
Bupivacaine hcl-ns 0.2%0.15USD ml
Bupivacaine 0.25% vial0.11USD ml
Bupivacaine 0.25% ampul0.1USD ml
Bupivacaine hcl-ns 0.125% bag0.1USD ml
Bupivacaine hcl-ns 0.25%0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8182835 No1998-09-182018-09-18Us
US8834921 No1998-09-182018-09-18Us
US9205052 No1998-09-182018-09-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point107-108 °CPhysProp
water solubility2400 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.41HANSCH,C ET AL. (1995)
pKa8.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0977 mg/mLALOGPS
logP3.31ALOGPS
logP4.52ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity90.19 m3·mol-1ChemAxon
Polarizability34.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.44 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Thuresson, B. and Egner, B.P.H.; U.S. Patent 2,792,399; May 14, 1957; assigned to AB Bofors, Sweden.
Thuresson, B. and Pettersson, B.G.; US. Patent 2,955.1 11; October 4,1960; assigned to AB
Bofors, Sweden.

US2955111
General References
  1. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB: Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006 Jul;105(1):217-8. [PubMed:16810015 ]
  2. Picard J, Meek T: Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia. 2006 Feb;61(2):107-9. [PubMed:16430560 ]
  3. Link [Link]
External Links
ATC CodesN01BB01N01BB51
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (147 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Bupivacaine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alprazolam.
AlprenololThe serum concentration of Bupivacaine can be increased when it is combined with Alprenolol.
AmiodaroneThe metabolism of Bupivacaine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amperozide.
AprepitantThe serum concentration of Bupivacaine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Aripiprazole.
ArmodafinilThe metabolism of Bupivacaine can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Bupivacaine can be increased when it is combined with Arotinolol.
ArtemetherThe metabolism of Bupivacaine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Asenapine.
AtazanavirThe metabolism of Bupivacaine can be decreased when combined with Atazanavir.
AtenololThe serum concentration of Bupivacaine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Bupivacaine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Azaperone.
AzelastineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bupivacaine.
AzithromycinThe metabolism of Bupivacaine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital.
BefunololThe serum concentration of Bupivacaine can be increased when it is combined with Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benzyl alcohol.
BetaxololThe serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.
BevantololThe serum concentration of Bupivacaine can be increased when it is combined with Bevantolol.
BexaroteneThe serum concentration of Bupivacaine can be decreased when it is combined with Bexarotene.
BisoprololThe serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.
BoceprevirThe metabolism of Bupivacaine can be decreased when combined with Boceprevir.
BopindololThe serum concentration of Bupivacaine can be increased when it is combined with Bopindolol.
BortezomibThe metabolism of Bupivacaine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bupivacaine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
BrimonidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brotizolam.
BufuralolThe serum concentration of Bupivacaine can be increased when it is combined with Bufuralol.
BupranololThe serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Buprenorphine.
BupropionThe metabolism of Bupivacaine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bupivacaine.
ButacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butorphanol.
CaffeineThe metabolism of Bupivacaine can be decreased when combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carisoprodol.
CarteololThe serum concentration of Bupivacaine can be increased when it is combined with Carteolol.
CarvedilolThe serum concentration of Bupivacaine can be increased when it is combined with Carvedilol.
CelecoxibThe metabolism of Bupivacaine can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Bupivacaine can be increased when it is combined with Celiprolol.
CeritinibThe serum concentration of Bupivacaine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Bupivacaine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloroprocaine.
ChloroquineThe metabolism of Bupivacaine can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Bupivacaine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Bupivacaine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Bupivacaine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Bupivacaine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Citalopram.
CitalopramThe metabolism of Bupivacaine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Bupivacaine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Bupivacaine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clidinium.
ClobazamThe metabolism of Bupivacaine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clomipramine.
ClomipramineThe metabolism of Bupivacaine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clorazepate.
ClotrimazoleThe metabolism of Bupivacaine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Bupivacaine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clozapine.
CobicistatThe serum concentration of Bupivacaine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Codeine.
ConivaptanThe serum concentration of Bupivacaine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Bupivacaine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Bupivacaine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Bupivacaine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapoxetine.
DarifenacinThe metabolism of Bupivacaine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Bupivacaine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Bupivacaine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Bupivacaine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Bupivacaine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desflurane.
DesipramineThe metabolism of Bupivacaine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Detomidine.
DexamethasoneThe serum concentration of Bupivacaine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Bupivacaine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydromorphine.
DiltiazemThe metabolism of Bupivacaine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Bupivacaine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxepin.
DoxycyclineThe metabolism of Bupivacaine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
DoxylamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Bupivacaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
DronedaroneThe metabolism of Bupivacaine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Drotebanol.
DuloxetineThe metabolism of Bupivacaine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Bupivacaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Bupivacaine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Efavirenz.
EliglustatThe metabolism of Bupivacaine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Bupivacaine.
EntacaponeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Entacapone.
EnzalutamideThe serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Bupivacaine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Bupivacaine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe serum concentration of Bupivacaine can be increased when it is combined with Esmolol.
EsomeprazoleThe metabolism of Bupivacaine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Eszopiclone.
EthanolBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bupivacaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine.
EthosuximideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Bupivacaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etorphine.
EtravirineThe serum concentration of Bupivacaine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flibanserin.
FluconazoleThe metabolism of Bupivacaine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluoxetine.
FluoxetineThe metabolism of Bupivacaine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Bupivacaine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Bupivacaine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Bupivacaine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fospropofol.
Fusidic AcidThe serum concentration of Bupivacaine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Bupivacaine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Halazepam.
HaloperidolThe metabolism of Bupivacaine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bupivacaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Bupivacaine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloperidone.
ImatinibThe metabolism of Bupivacaine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Bupivacaine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indalpine.
IndenololThe serum concentration of Bupivacaine can be increased when it is combined with Indenolol.
IndinavirThe metabolism of Bupivacaine can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Bupivacaine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isoflurane.
IsoniazidThe metabolism of Bupivacaine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Bupivacaine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Bupivacaine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Bupivacaine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketobemidone.
KetoconazoleThe metabolism of Bupivacaine can be decreased when combined with Ketoconazole.
LabetalolThe serum concentration of Bupivacaine can be increased when it is combined with Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levetiracetam.
LevobunololThe serum concentration of Bupivacaine can be increased when it is combined with Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levorphanol.
LidocaineThe metabolism of Bupivacaine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lofentanil.
LopinavirThe metabolism of Bupivacaine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bupivacaine.
LorcaserinThe metabolism of Bupivacaine can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Bupivacaine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Bupivacaine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Bupivacaine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Bupivacaine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Metaxalone.
MethadoneThe metabolism of Bupivacaine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methylphenobarbital.
MetipranololThe serum concentration of Bupivacaine can be increased when it is combined with Metipranolol.
MetoprololThe serum concentration of Bupivacaine can be increased when it is combined with Metoprolol.
MetyrosineBupivacaine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Bupivacaine can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam.
MifepristoneThe metabolism of Bupivacaine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
MirabegronThe metabolism of Bupivacaine can be decreased when combined with Mirabegron.
MirtazapineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bupivacaine.
MitotaneThe serum concentration of Bupivacaine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Bupivacaine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Bupivacaine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bupivacaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.
NabiloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nabilone.
NadololThe serum concentration of Bupivacaine can be increased when it is combined with Nadolol.
NafcillinThe serum concentration of Bupivacaine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nalbuphine.
NefazodoneThe metabolism of Bupivacaine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Bupivacaine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Bupivacaine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Bupivacaine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Bupivacaine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Bupivacaine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olanzapine.
OlaparibThe metabolism of Bupivacaine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olopatadine.
OmeprazoleThe metabolism of Bupivacaine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Opium.
OrphenadrineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Bupivacaine.
OsanetantThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Osanetant.
OsimertinibThe serum concentration of Bupivacaine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxazepam.
OxprenololThe serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxymorphone.
PalbociclibThe serum concentration of Bupivacaine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paliperidone.
PanobinostatThe metabolism of Bupivacaine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Bupivacaine can be decreased when combined with Pantoprazole.
ParaldehydeBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Bupivacaine.
ParoxetineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paroxetine.
ParoxetineThe metabolism of Bupivacaine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Bupivacaine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Bupivacaine can be increased when it is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pimozide.
PindololThe serum concentration of Bupivacaine can be increased when it is combined with Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pomalidomide.
PosaconazoleThe metabolism of Bupivacaine can be decreased when combined with Posaconazole.
PractololThe serum concentration of Bupivacaine can be increased when it is combined with Practolol.
PramipexoleBupivacaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bupivacaine.
PrilocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prochlorperazine.
PromazineThe metabolism of Bupivacaine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propoxycaine.
PropranololThe serum concentration of Bupivacaine can be increased when it is combined with Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Bupivacaine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quetiapine.
QuinidineThe metabolism of Bupivacaine can be decreased when combined with Quinidine.
QuinineThe metabolism of Bupivacaine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ramelteon.
RanolazineThe metabolism of Bupivacaine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bupivacaine.
RifabutinThe metabolism of Bupivacaine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Bupivacaine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Bupivacaine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Risperidone.
RitonavirThe metabolism of Bupivacaine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Bupivacaine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Romifidine.
RopiniroleBupivacaine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Bupivacaine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bupivacaine.
RotigotineBupivacaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Bupivacaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Bupivacaine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Bupivacaine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertraline.
SertralineThe metabolism of Bupivacaine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sevoflurane.
SildenafilThe metabolism of Bupivacaine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Bupivacaine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bupivacaine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sodium oxybate.
SotalolThe serum concentration of Bupivacaine can be increased when it is combined with Sotalol.
St. John's WortThe serum concentration of Bupivacaine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.
SulfisoxazoleThe metabolism of Bupivacaine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptBupivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TelaprevirThe metabolism of Bupivacaine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Bupivacaine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bupivacaine.
TenofovirThe metabolism of Bupivacaine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Bupivacaine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Bupivacaine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrodotoxin.
ThalidomideBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bupivacaine.
TheophyllineThe metabolism of Bupivacaine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiagabine.
TiclopidineThe metabolism of Bupivacaine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiletamine.
TimololThe serum concentration of Bupivacaine can be increased when it is combined with Timolol.
TipranavirThe metabolism of Bupivacaine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tizanidine.
TocilizumabThe serum concentration of Bupivacaine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bupivacaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Valproic Acid.
VemurafenibThe serum concentration of Bupivacaine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Bupivacaine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Bupivacaine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vilazodone.
VoriconazoleThe metabolism of Bupivacaine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zimelidine.
ZiprasidoneThe metabolism of Bupivacaine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med. 2010 Jan;20(1):16-21. doi: 10.1016/j.tcm.2010.03.002. [PubMed:20685573 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Prostaglandin e receptor activity
Specific Function:
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.
Gene Name:
PTGER1
Uniprot ID:
P34995
Molecular Weight:
41800.655 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Beloeil H, Gentili M, Benhamou D, Mazoit JX: The effect of a peripheral block on inflammation-induced prostaglandin E2 and cyclooxygenase expression in rats. Anesth Analg. 2009 Sep;109(3):943-50. doi: 10.1213/ane.0b013e3181aff25e. [PubMed:19690271 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gantenbein M, Attolini L, Bruguerolle B, Villard PH, Puyoou F, Durand A, Lacarelle B, Hardwigsen J, Le-Treut YP: Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5. [PubMed:10725304 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:16